APOL1-Mediated Kidney Disease (AMKD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 APOL1-Mediated Kidney Disease (AMKD) Market Outlook

Thelansis’s “APOL1-Mediated Kidney Disease (AMKD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential APOL1-Mediated Kidney Disease (AMKD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

APOL1-Mediated Kidney Disease (AMKD) Overview

Apolipoprotein L-1 (APOL1) variants pose a heightened risk of end-stage kidney disease (ESRD) among African American individuals. These coding variants are associated explicitly with non-diabetic chronic kidney disease, focal segmental glomerulosclerosis (FSGS), and HIV-associated nephropathy in patients of African descent. APOL1, a small 42 kd protein primarily found in the kidney and enriched in glomeruli, harbors two allelic variants: G1 (S342G and I384M) and G2 (N388del: Y389del), both altering the APOL1 protein sequence within an anti-trypanosome activity domain. The majority of individuals with recent African ancestry diagnosed with HIV-associated nephropathy (HIVAN), FSGS, and hypertension-attributed ESRD exhibit APOL1-associated kidney disease. Clinical studies on kidney transplantation reveal no significant correlation between APOL1 genotype and serum APOL1 protein levels or the presence of kidney disease.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: APOL1-Mediated Kidney Disease (AMKD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034